In a meta-analysis about the staging setting, PET/CT with PSMA-targeted agents showed a moderate sensitivity (71%) and high specificity (95%) for the detection of metastatic lymph nodes in patients with newly diagnosed intermediate to high-risk PCa [27]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.